Market Report Explored on Bacterial Pneumonia - Pipeline Review, H1 2016

Bacterial Pneumonia - Pipeline Review, H1 2016 ​is a new market research publication announced by Reportstack. This report provides an overview of the Bacterial Pneumonia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bacterial Pneumonia, complete with analysis by stage of development,mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bacterial Pneumonia and features dormant and discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

To access full report with TOC, please visit ​Bacterial Pneumonia - Pipeline Review, H1 2016.

Scope

- The report provides a snapshot of the global therapeutic landscape of Bacterial Pneumonia
- The report reviews pipeline therapeutics for Bacterial Pneumonia by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Bacterial Pneumonia

Reasons to buy

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Bacterial Pneumonia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned

Abera Bioscience AB Actelion Ltd Alvogen Korea Co., Ltd. Aridis Pharmaceuticals LLC Arsanis Biosciences GmbH AstraZeneca Plc Beijing Minhai Biotechnology Co., Ltd ContraFect Corporation Daiichi Sankyo Company, Limited Double Bond Pharmaceutical International AB Emergent BioSolutions Inc. Eurocine Vaccines AB FluGen, Inc. GlaxoSmithKline Plc Humabs BioMed SA ImmunoBiology Limited Indian Immunologicals Limited Integrated BioTherapeutics, Inc. Kyorin Pharmaceutical Co., Ltd. Lascco SA LG Life Science LTD. Liquidia Technologies, Inc. MedImmune, LLC Merck & Co., Inc. Mucosis B.V. Noxxon Pharma AG Panacea Biotec Limited Prometheon Pharma, LLC Sanofi Pasteur SA Serum Institute of India Limited SK Chemicals Co., Ltd. Sumitomo Dainippon Pharma Co., Ltd. Valneva SE Vaxxilon AG Virometix AG Walvax Biotechnology Co., Ltd. Wellstat Vaccines, LLC Wockhardt Limited

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###